Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Recce Pharmaceutical Limited ABN/ARBN Financial year ended: 74 124 849 065 30 June...
Appendix 4G
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4g-244
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
In the deck
Earlier from Recce Pharmaceuticals
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Change of Director's Interest Notices (x4)
- Cleansing Notice
- Application for quotation of securities - RCE
- Completion of Share Purchase Plan and Shortfall Notice
Later from Recce Pharmaceuticals
- Appendix 4E and FY26 Annual Report
- General Meeting Presentation
- Results of General Meeting
- 2026 Annual General Meeting
- Resolutions under section 249N of the Corporations Act
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals